Full text is available at the source.
Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials
How well GLP-1 receptor drugs work compared to DPP-4 inhibitors for managing type 2 diabetes: A review of clinical trials
AI simplified
Abstract
A pooled analysis of 13 randomized controlled trials involving 4,330 participants showed that GLP-1 agonists provide a 0.41% greater reduction in glycated hemoglobin compared to DPP-4 inhibitors.
- GLP-1 agonists resulted in an average weight loss of -2.15 kg compared to DPP-4 inhibitors.
- Participants using GLP-1 agonists experienced higher rates of gastrointestinal side effects.
- There was no increased risk of hypoglycemia associated with GLP-1 agonists compared to DPP-4 inhibitors.
- Switching from a DPP-4 inhibitor to a GLP-1 agonist led to an additional reduction in HbA1c of -0.69%.
- This switch also resulted in an average weight loss of -2.25 kg.
AI simplified